Development of daptomycin for Gram-positive infections

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 4, 2000, Pages 523-526

  Tally, Francis P ^a   DeBruin, Michael F ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CREATINE KINASE MM; DAPTOMYCIN; GLYCOPEPTIDE; METICILLIN; OXACILLIN; PENICILLIN G; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENTEROCOCCUS; GASTROINTESTINAL TOXICITY; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEPHROTOXICITY; NERVE FIBER DEGENERATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTANTIBIOTIC EFFECT; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG EVALUATION, PRECLINICAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 0033790259     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.4.523     Document Type: Article

References (32)

1. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
2. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
3. Daptomycin
4. Daptomycin: A novel agent for Gram-positive infections
5. Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY 146032)
6. The activity of daptomycin on Enterococcus faecium protoplasts: Indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis
7. Daptomycin disrupts membrane potential in growing Staphylococcus aureus
8. 2+ and albumin on these drugs
9. In vitro activity of daptomycin against resistant Gram-positive pathogens
10. Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level gentamicin-resistant enterococci
11. Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and synercid against methicillin-resistant and susceptible staphylococci, vancomycin-susceptible (VS) and resistant enterococci (VRE)
12. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin
13. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model
14. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains
15. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis
16. In vitro studies on resistance to the lipopeptide antibiotic daptomycin
17. In vivo efficacy of daptomycin against systemic infection induced by vancomycin-resistant Enterococcus faecalis (VRE) in the mouse
18. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination
19. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY147032
20. Treatment of experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin
21. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits
22. Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus
23. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin
24. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits
25. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis
26. LY146032 treatment of Clostridium difficile colitis in hamsters
27. LY146032 in a hamster model of Staphylococcus aureus pneumonia - Effect on in vivo clearance and mortality and in vitro opsonophagocytic killing
28. Pharmacodynamic and pharmacokinetic parameters (PKPs) affecting activity of LY146032 against Staphylococcus aureus
29. In vivo pharmacodynamic activity of daptomycin (DAP) against multiple bacterial pathogens
30. The pharmacodynamics of daptomycin as determined for Staphylococcus aureus in a mouse thigh infection model
31. Once-daily dosing decreases toxicity of daptomycin
32. Effect of protein binding of daptomycin on MIC and antibacterial activity